1. The potential of γδ CAR and TRuC T cells: An unearthed treasure.
- Author
-
Schamel WW, Zintchenko M, Nguyen T, Fehse B, Briquez PS, and Minguet S
- Subjects
- Humans, Animals, Neoplasms immunology, Neoplasms therapy, Hematologic Neoplasms therapy, Hematologic Neoplasms immunology, Receptors, Antigen, T-Cell, gamma-delta immunology, Immunotherapy, Adoptive methods, Receptors, Chimeric Antigen immunology, Receptors, Chimeric Antigen genetics, T-Lymphocytes immunology
- Abstract
Recent years have witnessed the success of αβ T cells engineered to express chimeric antigen receptors (CARs) in treating haematological cancers. CARs combine the tumour antigen binding capability of antibodies with the signalling functions of the T-cell receptor (TCR) ζ chain and co-stimulatory receptors. Despite the success, αβ CAR T cells face limitations. Possible solutions would be the use of γδ T cells and new chimeric receptors, such as TCR fusion constructs (TRuCs). Notably, γδ CAR T cells are gaining traction in pre-clinical and clinical studies, demonstrating a promising safety profile in several pilot studies. This review delves into the current understanding of γδ CAR and TCR fusion construct T cells, exploring the opportunities and challenges they present for cancer treatment., (© 2024 The Author(s). European Journal of Immunology published by Wiley‐VCH GmbH.)
- Published
- 2024
- Full Text
- View/download PDF